5'-O-acetyl-2',3'-dideoxyuridine | 102935-28-4

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 英文名称: 5'-O-acetyl-2',3'-dideoxyuridine
• 英文别名: [(2S,5R)-5-(2,4-dioxopyrimidin-1-yl)tetrahydrofuran-2-yl]methyl acetate；[(2S,5R)-5-(2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl acetate
• CAS: 102935-28-4
• 化学式: C₁₁H₁₄N₂O₅
• 分子量: 254.243
• InChiKey: LZFFPEHRPAJQHK-WCBMZHEXSA-N

物化性质

• 密度：
  1.332±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  84.9
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  5'-O-acetyl-2',3'-dideoxyuridine 在 吡啶 、 ammonium hydroxide 、 4-氯苯基二氯磷酸酯 作用下， 反应 77.0h， 生成 2,3-二脱氧胞啶
  参考文献：
  名称：

  嘧啶脱氧核糖核苷的各种3'-叠氮基，3'-氨基，2'，3'-不饱和和2'，3'-二脱氧类似物的合成及抗病毒活性。

  摘要：

  制备了嘧啶脱氧核糖核苷的各种3'-叠氮基，3'-氨基，2'，3'-不饱和，2'，3'-二脱氧和5取代的类似物并针对莫洛尼-鼠白血病病毒（M-MULV ），一种哺乳动物的T淋巴细胞逆转录病毒。在这些化合物中，胸苷的3'-叠氮基类似物，2'-脱氧-5-溴尿苷和2'-脱氧-5-碘尿苷，胸腺嘧啶和2'-脱氧胞苷的2'，3'-不饱和类似物，和2'，3'-二脱氧胞苷的活性最高，ED50分别为0.02、1.5、3.0、2.5、3.7和4.0 microM。这些活性化合物对高达100 microM浓度的宿主SC-1细胞无毒。胸腺嘧啶的3'-叠氮基类似物和2'-脱氧-5-溴尿苷也已在体外针对HTLV-III / LAV / AAV（“ AIDS” 病毒），发现其具有显着活性，ED50值分别为0.23和2.3 microM。讨论了构效关系。

  DOI：

  10.1021/jm00385a033
• 作为产物：
  描述：

  尿嘧啶核苷 在 palladium on activated charcoal 氢气 、 sodium methylate 、 对甲苯磺酸 作用下， 以 甲醇 为溶剂， 反应 21.0h， 生成 5'-O-acetyl-2',3'-dideoxyuridine
  参考文献：
  名称：

  Synthesis of 2',3'-dideoxyuridine via deoxygenation of 2',3'-O-(methoxymethylene)uridine

  摘要：

  DOI：

  10.1021/jo00256a056

文献信息

• [EN] PHOSPHAMIDE DERIVATIVE, METHOD FOR MANUFACTURING THE SAME, AND USES THEREOF<br/>[FR] DÉRIVÉ DE PHOSPHAMIDE, SON PROCÉDÉ DE FABRICATION ET SES UTILISATIONS<br/>[ZH] 一种磷酰胺衍生物及制备方法和用途
  申请人：SICHUAN HAISCO PHARMACEUTICAL CO LTD

  公开号：WO2017133517A1

  公开（公告）日：2017-08-10

  公开了一种磷酰胺衍生物及制备方法和用途。特别公开了一种通式(I)所示化合物及其药学上可接受的盐或立体异构体 (I)，其中，G、L、Q、s如说明书中所定义。
• Inhibition of <i>Mycobacterium tuberculosis</i>, <i>Mycobacterium bovis</i>, and <i>Mycobacterium </i><i>avium</i> by Novel Dideoxy Nucleosides
  作者：Dinesh Rai、Monika Johar、Naveen C. Srivastav、Tracey Manning、B. Agrawal、Dennis Y. Kunimoto、Rakesh Kumar

  DOI：10.1021/jm070391t

  日期：2007.9.1

  The prevalence of tuberculosis (TB) and mutidrug-resistant tuberculosis (MDR-TB) has been increasing, leading to serious infections, high mortality, and a global health threat. Here, we report the identification of a novel class of dideoxy nucleosides as potent and selective inhibitors of Mycobacterium bovis, Mycobacterium tuberculosis, and drug-resistant Mycobacterium tuberculosis. A series of 5-acetylenic derivatives of 2 ',3 '-dideoxyuridine (3-8) and 3 '-fluoro-2 ',3 '-dideoxyuridine (22-27) were synthesized and tested for their antimycobacterial activity against M. bovis, M. tuberculosis, and M. avium. 2 ',3 '-Dideoxyuridine possessing 5-decynyl, 5-dodecynyl, 5-tridecynyl, and 5-tetradecynyl substituents (4-7) exhibited the highest antimycobacterial activity against all three mycobacteria. In contrast, in the 3 '-fluoro-2 ',3 '-dideoxyuridine series, a 5-tetradecynyl analogue (26) displayed the most potent activity against these mycobacteria. Among other derivatives, 5-bromo-2',3'-dideoxycytidine (11), 5-methyl-2 ',3 '-dideoxycytidine (12). and 5-chloro-4-thio-2 ',3 '-dideoxyuridine (19) exhibited modest inhibition of M. bovis and M. tuberculosis. In the series of dideoxy derivatives of adenosine, guanosine, and purines, 2-amino-6-mercaptoethyl-9-(2,3-dideoxy-beta-D-glyceropentofuranosyl)purine (32) and 2-amino-4-fluoro-7-(2,3-dideoxy-beta-D-glyceropentofuranosyl)pyrrolo[2,3-d]pyrimidine (35) were the most efficacious against M. bovis and M. tuberculosis, and All. avium, respectively.
• WO2008/82440
  申请人：——

  公开号：——

  公开（公告）日：——
• Synthesis of Certain Heterodimers Expected as HIV-1 Reverse Transcriptase Inhibitors
  作者：D. Ladurée、E. Sugeac、C. Fossey、S. Schmidt、G. Laumond、A. M. Aubertin

  DOI：10.1081/ncn-120022675

  日期：2003.10

  Expected for the ability to inhibit HIV replication, we report the synthesis of two heterodimers of the general formula: [2NRTI]-C5-GLY-SUCCINYL-Npiperazinyl-[NNRTI] (18, 19) containing both a Nucleoside Reverse Transcriptase Inhibitor (10, 11) and a Non-Nucleoside Reverse Transcriptase Inhibitor (8) [Trovirdine Analogue belonging of the phenethyl thiazolyl thiourea class] connected through the "succinyl-glycine" spontaneously cleavable linker.
• Synthesis and Evaluation of “AZT-HEPT”, “AZT-Pyridinone”, and “ddC-HEPT” Conjugates as Inhibitors of HIV Reverse Transcriptase
  作者：Renée Pontikis、Valérie Dollé、Jean Guillaumel、Elsa Dechaux、Reine Note、Chi Hung Nguyen、Michel Legraverend、Emile Bisagni、Anne-Marie Aubertin、David S. Grierson、Claude Monneret

  DOI：10.1021/jm991125l

  日期：2000.5.1

  To test the concept that HIV reverse transcriptase could be effectively inhibited by "mixed site inhibitors", a series of seven conjugates containing both a nucleoside analogue component(AZT 1, ddC 2) and a nonnucleoside type inhibitor (HEPT analogue 12, pyridinone 27) were synthesized and evaluated for their ability to block HIV replication. The (N-3 and C-5)AZT-HEPT conjugates 15, 22, and 23 displayed 2-5 mu M anti-HIV activity, but they had no effect on the replication of HIV-2 or the HIV-1 strain with the Y181C mutation. The (C-5)AZT-pyridinone conjugates 34-37 were found to be inactive. In marked contrast, the ddC-HEPT molecule 26 displayed the same potency (EC50 = 0.45 mu M) against HTV-1 (wild type and the Y181C nevirapine-resistant strain) and HIV-2 in cell culture. No synergistic effect was-observed for these bis-substrate inhibitors, suggesting that the two individual inhibitor components in these molecules do not bind simultaneously in their respective sites. Interestingly, however, the results indicate that the AZT-HEPT conjugates and the ddC-HEPT derivative 26 inhibit reverse transcriptase (RT) in an opposite manner. One explanation for this difference is that the former compounds interact preferentially with the hydrophobic pocket in RT, whereas 26 (after supposed triphosphorylation) inhibits RT through binding in the catalytic site.